๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Spain
Clinical trial register · European Union · CTIS

Clinical Trials in Spain, 2026

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show โ€” this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12470 total CTIS records โ€” a stated recency window, not the full historical archive. Synced 23 Sep 2026, 03:16 UTC
2500
Shown in this register
most recently authorised
12,470
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1019 France 885 Germany 860 Italy 737 Poland 585 Netherlands 532
Narrow the registerReset
Phase
Phase I 555 Phase I/II 212 Phase II 727 Phase III 745 Phase IV 261
Lead sponsor
AstraZeneca AB 62 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 47 Pfizer Inc. 44 Novo Nordisk A/S 43
Member state
Spain 1019 France 885 Germany 860 Italy 737 Poland 585 Netherlands 532 Belgium 424 Czechia 332
All 28 states

Trials with a site in Spain

1019 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase III
A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia
2025-524209-34-00Chemotherapy induced thrombocytopenia
Jiangsu Hengrui Pharmaceuticals Co. Ltd.
Not possible to specify
France, Romania, Poland, Spain, Bulgaria
21/04/2026
Phase III
A Phase III, randomized, placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy followed by an Open Label Extension
2025-523481-24-00Participants with Progressive Supranuclear Palsy Richardsonโ€ฆ
Novartis Pharma AG
Nervous System Diseases
Netherlands, Germany, Spain, Italy, France, Belgium
21/04/2026
Phase I/II
A single-arm, open-label, multi-centre, phase I/II first-in-human study evaluating the safety and clinical activity of QEL-005, an autologous CAR T-regulatory cell therapy treatment targeting CD19, in patients with diffuse cutaneous systemic sclerosis (dcSSc) and in patients with difficult to treat rheumatoid arthritis (D2TRA).
2025-523971-46-00Diffuse cutaneous systemic sclerosis (dcSSc) Difficult to tโ€ฆ
Quell Therapeutics Limited
Musculoskeletal Diseases
Spain, Germany
21/04/2026
Phase II
Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)
2025-525068-13-00Chronic Kidney Disease
Universitair Medisch Centrum Groningen
Nutritional and Metabolic Diseases
Germany, Spain, Netherlands
21/04/2026
Phase I/II
C6461008 - AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA
2025-523524-53-00ADVANCED OR METASTATIC RENAL CELL CARCINOMA
Pfizer Inc.
Neoplasms
Germany, Spain
21/04/2026
Phase III
J3R-MC-YDAL - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes
2025-523659-73-00Obesity, Overweight
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Spain, Romania, Belgium, Czechia
21/04/2026
Phase II
Protocol Title: Efficacy and safety of once-weekly subcutaneous NNC0662-0419 in participants with type 2 diabetes โ€“ a dose-finding study
2025-523260-20-00type 2 diabetes
Novo Nordisk A/S
Hormonal diseases
Spain, Hungary, Portugal, Poland, Slovakia, Croatia
21/04/2026
Phase I/II
A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies
2025-523474-16-00Malignancies with Documented KRAS, BRAF and Other Selected โ€ฆ
Institut De Recherches Internationales Servier IRIS
Neoplasms
France, Spain, Denmark, Italy
21/04/2026
Phase III
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia
2025-524366-21-00treatment-naive Chronic Lymphocytic Leukemia
BeOne Medicines I GmbH
Neoplasms
Netherlands, Poland, Italy, Germany, Spain, Romania, Czechia, France, Sweden
20/04/2026
Phase II
A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)
2025-523793-16-00Homeostatic iron regulator gene-related hereditary hemochroโ€ฆ
CSL Behring LLC
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Austria, Poland, Spain, Germany, France, Ireland, Romania, Belgium, Italy, Czechia, Netherlands
20/04/2026
Phase I/II
Double-blind, randomized, placebo-controlled, study to evaluate the safety and efficacy of HRX215 in participants after major hepatectomy, preceded by two open pilot parts in participants after minor and after major hepatectomy due to colon carcinoma metastases
2025-523630-59-00colon carcinoma metastases
HepaRegeniX GmbH
Neoplasms
France, Spain, Germany
20/04/2026
Phase I
A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)
2025-522913-45-00Advanced relapsed or refractory ovarian cancer, Advanced reโ€ฆ
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Spain, France, Belgium, Germany
20/04/2026
Phase I
A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML).
2024-520125-36-00Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloโ€ฆ
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Spain, Hungary, Czechia, France, Italy, Belgium
20/04/2026
Phase III
A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigatorโ€™s Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced/Metastatic Urothelial Carcinoma
2024-520014-22-00Locally advanced/metastatic urothelial carcinoma
Merck Sharp & Dohme LLC
Neoplasms
Netherlands, Greece, Italy, Germany, Spain, Belgium, Sweden, France
20/04/2026
Phase II
An autologous and antigen-specific cell-based therapy of vitamin D3-treated and myelin-derived peptide loaded tolerogenic dendritic cells in subjects with progressive forms of multiple sclerosis: a phase IIa, open-label, self-controlled, multi-center clinical trial.
2025-522040-40-01Multiple Sclerosis
Universitair Ziekenhuis Antwerpen, Hospital Germans Trias I Pujol
Immune System Diseases
Belgium, Spain
20/04/2026
Phase III
C0371017 - A PHASE 3, NON-INVESTIGATIONAL PRODUCT, MULTI COUNTRY COHORT STUDY TO DESCRIBE THE LONG-TERM SAFETY AND EFFECTIVENESS OF A PRIOR SINGLE-DOSE TREATMENT WITH INVESTIGATIVE GIROCTOCOGENE FITELPARVOVEC OR FIDANACOGENE ELAPARVOVEC IN PARTICIPANTS WITH HEMOPHILIA A OR HEMOPHILIA B, RESPECTIVELY
2025-523660-21-00severe to moderately severe hemophilia B (FIX:C โ‰ค 2%), hemoโ€ฆ
Pfizer Inc.
Hemic and Lymphatic Diseases
Italy, Germany, France, Spain, Sweden, Greece
20/04/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Amyotrophic Lateral Sclerosis
2025-524002-16-00Amyotrophic Lateral Sclerosis
Ferrer Internacional S.A., Prilenia Therapeutics B.V.
Nervous System Diseases
Belgium, Netherlands, Poland, France, Germany, Ireland, Italy, Sweden, Spain
20/04/2026
Phase III
J4G-MC-JZVD - FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration.
2025-522855-25-00Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neโ€ฆ
Eli Lilly & Co.
Neoplasms
Italy, Poland, Denmark, Czechia, France, Hungary, Germany, Netherlands, Spain
20/04/2026
Phase II
A Multicentre, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of MaaT013 in Ruxolitinib-Refractory or Intolerant Paediatric and Adolescent participants with Gastrointestinal Acute Graft-versus-Host Disease
2025-524302-15-00Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)
MaaT PHARMA
Digestive System Diseases
Netherlands, Italy, France, Spain
17/04/2026
Phase III
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2)
2025-522748-42-00Ovarian cancer
Incyte Corp.
Neoplasms
Ireland, Poland, France, Netherlands, Spain, Italy, Germany, Belgium
17/04/2026
Phase III
Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).
2025-523717-29-00HFpEF or HFmrEF and obesity
Novo Nordisk A/S
Cardiovascular Diseases
Denmark, Greece, Bulgaria, Italy, Netherlands, Spain, Poland, Czechia, Germany, France
17/04/2026
Phase I
A Phase 1 Study of AIR-001 in Adults with AATD.
2025-523558-14-00Alpha-1 Antitrypsin Deficiency
Airna Corp.
Respiratory Tract Diseases
Sweden, Ireland, Spain, Netherlands, Portugal, Germany
17/04/2026
Phase III
A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naรฏve Adult Participants Who Require Red Blood Cell Transfusions
2025-523544-12-00Myelodysplastic neoplasms/syndromes (MDS)
Takeda Development Center Americas Inc.
Hemic and Lymphatic Diseases
France, Belgium, Germany, Italy, Bulgaria, Ireland, Lithuania, Norway, Romania, Hungary, Spain, Greece, Poland, Netherlands
17/04/2026
Phase II
Omalizumab for monotherapy treatment of patients with food allergies to plant-based foods due to sensitization to LTP and profilin
2025-524629-42-00Categoria 2, Patients with vegetable allergies due to sensiโ€ฆ
Fundacion Publica Andaluza Para La Investigacion De Malaga En Biomedicina Y Salud
Not possible to specify
Spain
17/04/2026
Phase I/II
An open-label, multi-center, phase I/II study of GVV858 as a single agent and in combination with endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and other advanced solid tumors
2025-521911-38-00Advanced HR+/HER- breast cancer
Novartis Pharma AG
Neoplasms
Italy, Germany, France, Czechia, Denmark, Spain
16/04/2026
Phase I
A study to evaluate how well single and multiple doses of S072 are tolerated in healthy adult participants
2025-525039-15-01Pain
Sea4us Biotecnologia E Recursos Marinhos S.A.
Anesthesia and Analgesia
Spain
16/04/2026
Phase III
The INFLUENCE Trial: Improving EveNt Free Survival by Optimizing FLUdarabine Exposure during LymphodepletioN for CAR T CEll Therapy: a randomized, multi-center study of children and young adults with B-cell acute lymphoblastic leukemia
2025-523096-34-00B-cell Acute Lymphoblastic Leukemia
Prinses Maxima Centrum voor Kinderoncologie B.V.
Hemic and Lymphatic Diseases
Spain, Germany, Netherlands
16/04/2026
Phase III
EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY- BIASED ULTRA LONG-ACTING GLP-1 RA IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)
2025-523975-48-00Obesity
Metsera Inc.
Nutritional and Metabolic Diseases
Czechia, Bulgaria, Slovakia, Spain, Hungary, Germany, Romania, Poland
16/04/2026
Phase I/II
Multicentre, open-label, phase 1/2 study of LB-208, selective antagonist of the serotonin 5-hydroxytryptamine receptor 1B (HTR1B), in adults with relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)
2025-523396-38-00Relapse or refractory (r/r) acute myeloid leukaemia (AML) aโ€ฆ
Aop Orphan Pharmaceuticals GmbH
Neoplasms
Spain
15/04/2026
Phase II
Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Hypochondroplasia: ACCEL OLE
2025-523509-13-00Hypochondroplasia
Qed Therapeutics Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Norway
15/04/2026
Phase III
A Prospective, Multi-National, Randomized, Double-Blind, Crossover Study to Evaluate the Efficacy and Safety of Gadopiclenol-enhanced MRA Compared to Gadoterate Meglumine-enhanced MRA in the Assessment of Steno-occlusive Disease in Adult Patients with Suspected Vascular Disease
2024-518835-13-00Suspected Vascular Disease of supra-aortic (carotid/vertebrโ€ฆ
Guerbet, Bracco Imaging S.p.A.
Cardiovascular Diseases
Italy, France, Czechia, Hungary, Spain, Germany, Poland
15/04/2026
Phase III
A Phase 3 randomized, double-blind, placebo-controlled, parallel group, multicenter study with open-label extension to evaluate the efficacy and safety of fenfluramine hydrochloride in study participants with Rett syndrome
2025-523157-34-00Rett syndrome
UCB Biosciences Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Poland, France, Hungary, Belgium, Italy, Germany
15/04/2026
Phase I/II
A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors.
2025-522318-21-00Neoplasms, Colorectal
Glaxosmithkline Research & Development Limited
Neoplasms
Italy, Denmark, Spain, Sweden, Netherlands, France
14/04/2026
Phase I
A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in people with advanced cancer
2025-521000-22-00Patients with advanced malignancies
Novartis Pharma AG
Neoplasms
Spain, Italy, France
14/04/2026
Phase II
Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group, Adaptive Proof-of-concept, Dose-selecting Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intranasal Cenegermin (recombinant human Nerve Growth Factor [rhNGF]) in Adult Participants with subacute moderate to severe Traumatic Brain Injury (TBI).
2025-522692-29-00Subacute Moderate to Severe Traumatic Brain Injury (TBI)
Dompe' Farmaceutici S.p.A.
Nervous System Diseases
Italy, Denmark, Finland, France, Germany, Spain, Sweden, Poland
14/04/2026
Phase I/II
Phase 1/2A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients with Advanced Solid Tumors
2025-524111-37-00advanced solid tumors
Ottimo Pharma Limited
Neoplasms
Ireland, Spain, Portugal
14/04/2026
Phase II
A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina-S) in Participants with Non-Small Cell Lung Cancer
2025-522107-18-00Locally advanced or metastatic Non-Small Cell Lung Cancer
Genmab A/S
Neoplasms
Germany, Hungary, Netherlands, France, Italy, Belgium, Spain, Poland
14/04/2026
Phase II
Standardized Phleum pratense in TBU/ml in liquid formulation for sublingual immunotherapy: Phase II, randomized dose determination clinical trial. DEDO-G Study.
2025-522730-31-00Allergic rhinitis/rhinoconjunctivitis caused by grass polenโ€ฆ
Asac Pharmaceutical Inmunology S.A.
Immune System Diseases
Spain
14/04/2026
Phase II
A Phase 2, multicenter, open label, non-randomized study to evaluate the efficacy and safety of extended dosing of belantamab mafodotin in different combinations with standard of care regimens in participants with relapsed-refractory multiple myeloma (DREAMM-15)
2025-523117-28-00Relapsed or Refractory Multiple Myeloma
Glaxosmithkline Research & Development Limited
Neoplasms
France, Germany, Greece, Netherlands, Spain
13/04/2026
Phase I
A study in people with advanced cancer to test how well different doses of BI 3819026 are tolerated when taken alone and together with ezabenlimab
2025-522953-21-00unresectable advanced or metastatic solid cancer
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Spain
13/04/2026
Phase III
A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures
2025-524038-24-00Focal Epilepsy
Praxis Precision Medicines Inc.
Nervous System Diseases
Poland, Germany, Czechia, Italy, Spain
10/04/2026
Phase II
A Phase 2b, Randomized, Double blind, Placebo controlled, Parallel group, Multicenter, Dose ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Adult Participants with Uncontrolled Moderate to Severe Eosinophilic Asthma
2025-523180-38-00Uncontrolled Moderate to Severe Eosinophilic Asthma
Kymera Therapeutics Inc.
Immune System Diseases
Spain, Romania, Slovakia, Poland, Germany, Italy, Belgium, Austria
10/04/2026
Phase I
A clinical trial to learn how liver function affects the blood levels of DAK539 in people with advanced cancer
2025-521001-40-00Advanced Malignancies and Hepatic Impairment
Novartis Pharma AG
Neoplasms
Spain, France, Italy
09/04/2026
Phase I
Phase 1, Open-Label, single arm (Non-comparator) Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Oral Gepotidacin in Addition to Antibacterial Standard of Care in Pediatric Participants from 2 to less than 12 years of age with a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis with Antibiotics
2025-522916-17-00Urinary Tract Infections
Glaxosmithkline Research & Development Limited
Bacterial Infections and Mycoses
Spain, Poland
09/04/2026
Phase I/II
PHASE I/IIa CLINICAL TRIAL FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASE WITH A NEW GENERATION OF MESENCHYMAL STROMAL CELLS ECTOPICALLY EXPRESSING CXCR4 AND IL-10 IN STEROID-REFRACTORY AND INTOLERANT OR RUXOLITINIB-REFRACTORY PATIENTS
2025-523139-21-00Patients who have developed acute GVHD refractory to corticโ€ฆ
Fundacion Instituto De Investigacion Sanitaria De Navarra
Immune System Diseases
Spain
09/04/2026
Phase I/II
A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Malignancies
2025-523547-35-00Advanced Solid Tumor Malignancies
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Spain
09/04/2026
Phase II
A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Adults with Non-Small Cell Lung Cancer in Combination with Pembrolizumab.
2025-522867-13-00Non Small Cell Lung Cancer
Merus B.V.
Not possible to specify
Spain, Belgium, Netherlands, Poland, Italy, France
09/04/2026
Phase I/II
C6461020 - An Interventional Open-Label Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 in combination with Different Anticancer Agents in Participants with Advanced Solid Tumors
2025-523526-40-00Advanced Solid Tumors
Pfizer Inc.
Neoplasms
Italy, Spain, France, Germany
09/04/2026
Phase I/II
C6461013 - An Interventional Open-label Phase 1b/2 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 as Monotherapy and Combination Therapy in Adult Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma
2025-523525-17-00Unresectable Locally Advanced or Metastatic Hepatocellular โ€ฆ
Pfizer Inc.
Neoplasms
Spain, Italy, Germany, France
09/04/2026
Phase III
A randomized, Phase 3, open-label study to investigate pharmacokinetics, safety, and efficacy of subcutaneous compared to intravenous frexalimab in adult participants with multiple sclerosis.
2024-519304-28-00Multiple Sclerosis
Sanofi-Aventis Recherche & Developpement
Nervous System Diseases
Belgium, Spain, Italy
08/04/2026
Phase II
ETOP 29-25 START-lung: A multicentre phase II trial of tarlatamab in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2.
2025-522288-13-00Patients with pretreated extensive-stage small cell lung caโ€ฆ
ETOP IBCSG Partners Foundation
Neoplasms
France, Greece, Spain, Italy
08/04/2026
Phase III
C6461004 - A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER
2025-523522-41-00Extensive-Stage Small Cell Lung Cancer
Pfizer Inc.
Neoplasms
France, Italy, Germany, Spain
07/04/2026
Phase III
Sevoflurane vs. propofol for general Anesthesia in patients with acute ischemic stroke treated with endoVascular treatmEnt (SAVE trial)
2025-523709-13-00Acute ischemic stroke
Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
Anesthesia and Analgesia
Spain
07/04/2026
Phase III
A multicenter, randomized, double-blind, parallel group, placebo-controlled study of the efficacy and safety of early depemokimab initiation as add-on treatment in COPD patients with type 2 inflammation.
2025-521108-23-00Chronic Obstructive Pulmonary Disease
Glaxosmithkline Research & Development Limited
Respiratory Tract Diseases
Germany, Belgium, Netherlands, Denmark, Spain, Greece, Poland, Hungary, France, Italy, Bulgaria, Romania
07/04/2026
Phase IV
Application of radiomics in molecular imaging (18F-FDG-PET/CT) for diagnosis and follow-up of cardiovascular device infections: PREDICT study
2025-524624-21-00Cardiovascular device infections
Fundacio De Recerca Clinic Barcelona-Institut Dโ€™Investigacions Biomediques August Pi I Sunyer
Virus Diseases
Spain
07/04/2026
Phase III
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and knee osteoarthritis (AMAZE 5)
2024-520444-42-00Overweight or obesity, and knee osteoarthritis
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Italy, Greece, Spain, Bulgaria, Denmark, Poland
07/04/2026
Phase III
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and knee osteoarthritis (AMAZE 6)
2024-520445-23-00Overweight or obesity, and knee osteoarthritis
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Greece, Poland, Spain, Bulgaria, Italy, Denmark
07/04/2026
Phase III
Multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of filgotinib in children and adolescents from 8 years to less than 18 years of age with polyarticular-course juvenile idiopathic arthritis
2024-511593-70-00Polyarticular-course juvenile idiopathic arthritis
Alfasigma S.p.A.
Musculoskeletal Diseases
Spain, Bulgaria, France, Belgium, Germany, Greece, Italy, Poland, Hungary, Czechia
07/04/2026
Phase III
EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY- BIASED ULTRA LONG-ACTING GLP-1RA IN PEOPLE WITH OVERWEIGHT OR OBESITY: A PHASE 3, MULTI-CENTER RANDOMIZED, CONTROLLED TRIAL (VESPER-4)
2025-523974-18-00Obesity
Metsera Inc.
Nutritional and Metabolic Diseases
Germany, Hungary, Slovakia, Poland, Spain, Czechia, Romania, Bulgaria
02/04/2026
Phase II
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of surlorian (ARM210, S48168) in Adults with Autosomal Dominant RYR1-Related Myopathy
2025-522343-18-00Autosomal Dominant RYR1-Related Myopathy
Rycarma Therapeutics Inc.
Musculoskeletal Diseases
Netherlands, Spain, France, Germany
02/04/2026
Phase III
A Phase 3, Multicenter, Double-Blinded, Randomized Study to Evaluate REGN7508, a Factor XI Monoclonal Antibody, Versus Acetylsalicylic Acid for Prophylaxis of Symptomatic Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-ASPEN)
2025-520479-25-00Symptomatic Venous Thromboembolism (VTE)
Regeneron Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Greece, Italy, Spain
01/04/2026
Phase III
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Zasocitinib in Pediatric Participants Aged 4 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis
2025-522567-15-00Plaque Psoriasis
Takeda Development Center Americas Inc.
Skin and Connective Tissue Diseases
Spain, Poland, Germany, Italy
01/04/2026
Phase I
A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma
2025-522523-96-00T-cell Non-Hodgkin Lymphoma, Cutaneous T-cell lymphoma (CTCโ€ฆ
Kyowa Kirin Inc.
Neoplasms
Spain, Italy
01/04/2026
Phase II
A Phase 2, randomized, placebo-controlled, double-blind clinical study to evaluate efficacy and safety of LAD328 in adult subjects with moderate to severe hidradenitis suppurativa
2025-521865-29-00moderate-to-severe hidradenitis suppurativa
Almirall S.A.
Skin and Connective Tissue Diseases
Bulgaria, Spain, France, Poland, Germany
01/04/2026
Phase II
A Phase 2, Dose Ranging, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients with Moderate to Severe Hidradenitis Suppurativa (COMPASS 2 - HS)
2025-522440-41-00Hidradenitis Suppurativa
Bluefin Biomedicine Inc.
Skin and Connective Tissue Diseases
Spain, Germany, Czechia, Poland, Bulgaria
31/03/2026
Phase I/II
Phase 1/2 Investigation Of Novel Experimental Regimen in Amyotrophic Lateral Sclerosis (PIONEER-ALS): An Open-Label, Uncontrolled, Multicenter Study to Assess the Safety and Tolerability of Two Doses of VTx-002.
2025-522697-37-00Amyotrophic Lateral Sclerosis
VectorY Therapeutics B.V.
Nervous System Diseases
Netherlands, Belgium, Spain
31/03/2026
Phase I
SIE-1
2025-523269-31-00Hormone receptor-positive early breast cancer in post-menopโ€ฆ
Laboratorios Farmaceuticos Rovi S.A.
Neoplasms
Spain
31/03/2026
Phase I/II
A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR)
2024-519786-22-01metastatic non-small cell lung cancer (NSCLC)
AstraZeneca AB
Neoplasms
Germany, Spain, France, Poland, Belgium, Netherlands, Italy
30/03/2026
Phase I/II
A Phase I/II, Modular, Open-Label, Multi-Centre Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD9750 as Monotherapy and in Combination with Other Anticancer Agents in Participants with Metastatic Prostate Cancer (ANDROMEDA)
2024-516976-14-00Metastatic Prostate Cancer
AstraZeneca AB
Male Urogenital Diseases
Netherlands, Spain
30/03/2026
Phase IV
Combined impact of cardiovascular polypill treatment and a specific nurse education program on adherence to therapy in patients with ACS: a randomized study
2025-524751-32-00Acute coronary syndrome
Fundacion Epic
Cardiovascular Diseases
Spain
30/03/2026
Phase III
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Azetukalner in Major Depressive Disorder
2025-523618-10-00Major Depressive Disorder
Xenon Pharmaceuticals Inc.
Mental Disorders
Finland, Poland, Romania, Slovakia, Spain, Germany
30/03/2026
Phase IV
TheRapeutic StrAtegies for Obstructive SleeP Apnea in Older Adults with OverweigHt or Obesity: A RandomizEd Clinical TriaL (RAPHAEL study)
2025-524819-37-00obstructive sleep apnea
Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre
Respiratory Tract Diseases
Spain
30/03/2026
Phase III
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure (AMAZE 3)
2024-520442-36-00Overweight or obesity, and obstructive sleep apnoea not treโ€ฆ
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Denmark, Poland, Spain, Germany
30/03/2026
Phase I
Phase 1, Randomized, Open-label, Single center study to evaluate Pharmacokinetic and Bioequivalence of Levonorgestrel Vaginal Delivery System in Healthy Female Volunteers after different days of use
2025-524330-25-00No medical condition
Chemo Research S.L.
Not possible to specify
Spain
27/03/2026
Phase III
Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRฮฑ-high and AZD5335 Versus Investigatorโ€™s Choice Chemotherapy in FRฮฑ-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)
2025-520466-22-00Advanced Platinum-resistant Epithelial Ovarian Cancer
AstraZeneca AB
Pathological Conditions, Signs and Symptoms
Ireland, Greece, Czechia, France, Sweden, Belgium, Denmark, Spain, Italy, Germany
27/03/2026
Phase III
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigatorโ€™s Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy
2024-519818-31-01Endometrial Cancer Advanced, Recurrent, Metastatic, or Primโ€ฆ
Genmab A/S
Neoplasms
Poland, Denmark, Finland, Lithuania, France, Germany, Spain, Belgium, Greece, Norway, Italy
26/03/2026
Phase IV
Dexamethasone for the treatment of traumatic brain injured patients with brain contusions and pericontusional edema: Study protocol for a prospective, randomized and double blind trial
2025-520887-17-00Post-traumatic brain contusion with edema
University Hospital Son Espases
Nervous System Diseases
Spain
26/03/2026
Phase II
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Proof of Concept (POC) Study Evaluating the Safety, Tolerability, and Efficacy of Nintedanib Solution for Inhalation (AP02) in Participants with Idiopathic Pulmonary Fibrosis (IPF) (AURA-IPF)
2025-523431-19-00Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.
Respiratory Tract Diseases
Germany, Italy, Spain, Ireland
26/03/2026
Phase III
Clinical trial to evaluate the efficacy and safety of Depigoid DUO Grass-Mix/Olea (1000 DPP/mL + 1000 DPP/mL) compared with placebo in patients suffering from allergic rhinoconjunctivitis with or without asthma due to clinically relevant sensitisation to grass and olive pollen.
2025-521709-42-00Allergic rhinoconjunctivitis with or without asthma due to โ€ฆ
LETI Pharma S.L.U.
Immune System Diseases
Spain, Portugal
25/03/2026
Phase III
Clinical trial to evaluate the efficacy and safety of Depigoid Grass-Mix at 1000 DPP/mL and Depigoid FORTE Grass-Mix at 3000 DPP/mL compared with placebo in patients suffering from allergic rhinoconjunctivitis with or without controlled asthma due to clinically relevant sensitisation to grass pollen.
2025-521736-10-00Allergic rhinoconjunctivitis with or without controlled astโ€ฆ
LETI Pharma S.L.U.
Immune System Diseases
Portugal, Spain
25/03/2026
Phase IV
Randomized, multicenter, open-label clinical trial to evaluate the clinical and microbiological impact of methenamine hippurate as an alternative prophylaxis to antibiotics in the management of recurrent urinary tract infections in women
2025-523922-42-00recurrent urine infections
Consorci Mar Parc De Salut De Barcelona
Female Urogenital Diseases and Pregnancy Complications
Spain
25/03/2026
Phase III
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study of Barzolvolimab in Participants with Cold Induced Urticaria and Symptomatic Dermographism (EMBARQ-COLDU and SD)
2025-522583-32-00Cold-Induced Urticaria and Symptomatic Dermographism
Celldex Therapeutics Inc.
Skin and Connective Tissue Diseases
Germany, Lithuania, Spain, Poland
25/03/2026
Phase II
An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)
2025-523803-31-00Advanced non-small cell lung cancer (NSCLC)
Shanghai Henlius Biotech Inc.
Therapeutics
Italy, Romania, Poland, Spain, France
25/03/2026
Phase II
A Phase 2, randomized, placebo-controlled, double-blind clinical study to evaluate efficacy and safety of LAD603 in adult subjects with severe to very severe alopecia areata
2025-523342-27-00Alopecia areata
Almirall S.A.
Skin and Connective Tissue Diseases
Bulgaria, Romania, Poland, Germany, Spain
24/03/2026
Phase I
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants with Advanced Solid Tumors
2025-523931-21-00Advanced Malignant Solid Tumors
Genmab A/S
Neoplasms
Spain
24/03/2026
Phase III
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure (AMAZE 4)
2024-520443-16-00Overweight or obesity, and obstructive sleep apnoea treatedโ€ฆ
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Poland, Spain, Germany
24/03/2026
Phase III
J3R-MC-YDAF - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants with Obesity or Overweight, and Type 2 Diabetes
2025-523658-15-00Obesity, Overweight
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Germany, Spain, Poland, Czechia, Slovakia
24/03/2026
Phase III
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction
2025-522475-28-00Pulmonary Hypertension (PH) with Heart Failure with preservโ€ฆ
Tenax Therapeutics Inc.
Cardiovascular Diseases
France, Italy, Germany, Czechia, Austria, Poland, Hungary, Bulgaria, Spain
24/03/2026
Phase III
AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
2025-523461-17-01LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Pfizer Inc.
Neoplasms
France, Italy, Hungary, Greece, Czechia, Spain, Poland, Germany
24/03/2026
Phase II
CHARACTERIZATION OF ASTROCYTE REACTIVITY WITH [18F]F-DED PET IN NEURODEGENERATIVE DISEASES
2025-523284-37-00Dementia, Autosomal Dominant Alzheimer's Disease, Sporadic โ€ฆ
Barcelonabeta Brain Research Center
Nervous System Diseases
Spain
24/03/2026
Phase I
A study to investigate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of a CD19/CD20 T-cell engager in participants with B-cell driven ARD.
2025-522932-15-00Systemic Lupus Erythematosus
Glaxosmithkline Research & Development Limited
Immune System Diseases
Germany, France, Italy, Spain, Poland
23/03/2026
Phase II
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)
2025-520902-37-00Non-small cell lung cancer stage IV
Merck Sharp & Dohme LLC
Neoplasms
Italy, Spain, Poland, France
23/03/2026
Phase III
Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02).
2025-523085-24-00Biliary Tract Cancer
AstraZeneca AB
Neoplasms
Germany, Poland, Italy, Belgium, France, Netherlands, Spain
23/03/2026
Phase III
A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study With a Double-Blind Extension Evaluating Efficacy and Safety of Lebrikizumab Administered to Adult Patients With Nummular Eczema who are not Adequately Controlled With Topical Corticosteroids or When This Treatment is not Medically Advisable (LUMINE)
2025-522403-17-00Nummular Dermatitis
Almirall S.A.
Skin and Connective Tissue Diseases
Italy, Bulgaria, Spain, Germany, Poland, France
23/03/2026
Phase II
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib plus Ribociclib plus Fulvestrant Versus Placebo plus Ribociclib plus Fulvestrant in Patients with Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer with Chromosome 8P Loss and Without a PIK3CA Mutation
2025-523013-28-00Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negativโ€ฆ
F. Hoffmann-La Roche AG
Neoplasms
France, Italy, Poland, Germany, Spain
23/03/2026
Phase II
A Phase 2 Study of ACR-368 Therapy in Subjects with Endometrial Cancer
2025-524542-10-00Endometrial cancer
Acrivon Therapeutics Inc.
Neoplasms
Italy, Germany, Spain, France
23/03/2026
Phase I
A clinical study to test MEN2501 in patients with treatment-resistant ovarian cancer
2025-524168-39-00โ€‹โ€‹Platinum-Resistant ovarian cancerโ€‹
Stemline Therapeutics Inc.
Neoplasms
Spain
23/03/2026
Phase III
C6461003 - AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAรVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER
2025-523521-18-00Metastatic Colorectal Cancer
Pfizer Inc.
Neoplasms
Spain, Belgium, France, Italy, Netherlands, Germany, Poland, Denmark
23/03/2026
Phase I
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
2024-519862-33-01Platinum-resistant ovarian cancer (PROC), Advanced renal ceโ€ฆ
Oncusp Therapeutics Inc.
Neoplasms
Denmark, Spain
23/03/2026
Phase II
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants with Active Psoriatic Arthritis
2025-523141-10-00Active Psoriatic Arthritis
Janssen Cilag International
Immune System Diseases
Spain, Poland, Czechia, Germany, Hungary
20/03/2026
Rows per page Showing 401–500 of 1019
Previous 3 4 5 6 7 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-europe/country/spain?page=5

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,470 trial records at the last sync on 23 Sep 2026, 03:16 UTC; this register shows the 2,500 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 1,019 of those trials with a site in Spain.

How many recently authorised EU trials have a site in Spain?

1,019 of the 2,500 most recently authorised trials in this register list a site in Spain; 425 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.